Acute myeloid leukemia (AML) is a cancer with a high mortality rate. AML affects blood cells in the bone marrow and has a five-year survival rate of ≈24% \[[@b1-dic.212252]\]. Standard treatment strategies for AML include chemotherapy, radiotherapy, and hematopoietic stem cell transplantation \[[@b2-dic.212252]\]. Due to the heterogeneous population of cancer cells and a lack of understanding of AML, therapies are often not successful.

The pathogenesis of AML is not clear and is controversial. Some authors believe that AML arises as a result of transformed hematopoietic stem cells, whereas others believe AML to be a result of genetic events occurring in mature progenitor cells \[[@b3-dic.212252]\].

For the past several decades, experimental data have shown that a subpopulation of cancer cells called cancer stem cells (CSCs) possess all the characteristics of normal stem cells (self-renewal, differentiation into various cell types) and may play a part in the development of cancer. Hence, researchers are attempting to better delineate the scientific understanding of the biology of CSCs and their role in cancer development.

Recently, researchers from the University of Rochester Medical Center (New York, NY, USA) reported that leukemia stem cells (LSCs), in comparison with non-tumorigenic cells, typically have a lower rate of energy metabolism and lower cellular oxidative status with low levels of reactive oxygen species (termed "ROS-low"). Furthermore, it was shown that LSCs overexpress the gene BCL-2, an inhibitor of mitochondrial-initiated apoptosis that has been shown to confer chemoresistance in cancer cells, so ROS-low LSCs aberrantly overexpress BCL-2. In that study, the authors demonstrated that treatment using small molecular inhibitors of BCL-2 could impair the metabolic activity of chemotherapy-resistant LSCs, resulting in the eradication of BCL-2. Hence, reduced oxidative phosphorylation and selective eradication of quiescent LSCs is possible through BCL-2 inhibition. These results were published on 17 January 2013 in *Cell Stem Cell*\[[@b4-dic.212252]\]. These findings could be of appreciable importance if the *sui generis* physiology of ROS-low LSCs can provide an avenue to be exploited by selective drug targeting via disruption of the BCL-2-dependent oxidative phosphorylation in CSCs.

One of the major difficulties in developing effective cancer therapies is the inability to kill cancer cells without damaging normal cells. Hence, researchers have attempted to utilize the "signature" aspects of cancer as unique targets for therapy development (i.e., overexpression of certain markers, activation/ deactivation of genes). In this case, targeting the metabolism of LSCs may be relevant for the treatment of AML. However, the variability within and between patients with ROS-low CSC during disease pathogenesis must be determined with regard to clinical applicability. Furthermore, whether or not this strategy is applicable towards the treatment of other cancers remains to be elucidated.

A low oxidative state as a potentially frequent property of CSC and the lack of glycolytic activity in stem cells may be inherent features of cancers. If this hypothesis is scientifically valid, then therapeutic strategies based on the assumption that tumors are reliant preferentially on glycolysis may fail the null hypothesis. Moreover, the paradoxical dependence on oxidative phosphorylation of the ROS-low LSC-enriched subset of CSC is part of a capacious metabolic adaptation of these cells because they successfully maintain survival despite a dramatically reduced overall metabolic rate. Identification of BCL-2 inhibitors as LSC targeting agents (together with the apparent absence of significant toxicity to normal cells) is intriguing because it provides a basis for the investigation of therapies at disease stages where targeting residual LSCs may be essential, such as in consolidation therapy or maintenance treatment during remission.

Nonetheless, the findings described by Lagadinou et al. in 2013 \[[@b4-dic.212252]\] are provocative and a syllogistic biomedical step forward towards unraveling the understanding of CSCs and their role in the development and progression of cancer.
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